ONC restructures as HITECH funding dries up

The Office of the National Coordinator for Health IT is moving forward with restructuring as HITECH’s health IT infrastructure and program investments draw to a close.

Under the new structure, instead of nine offices reporting up through deputy national coordinators, a total of 10 offices will be headed by a director reporting directly to National Health IT Coordinator Karen DeSalvo, MD, MPH, MSc and Deputy National Coordinator Jacob Reider, MD.

The 10 offices, and their directors, are:

  • Office of Care Transformation: Kelly Cronin
  • Office of the Chief Privacy Officer: Joy Pritts
  • Office of the Chief Operating Officer: Lisa Lewis
  • Office of the Chief Scientist: Doug Fridsma, MD, PhD
  • Office of Clinical Quality and Safety: Judy Murphy, RN
  • Office of Planning, Evaluation and Analysis: Seth Pazinski
  • Office of Policy: Jodi Daniel
  • Office of Programs: Kim Lynch
  • Office of Public Affairs and Communications: Nora Super
  • Office of Standards and Technology: Steve Posnack

“This functional realignment will improve the overall effectiveness and efficiency of ONC by combining similar functions, elevating critical priority functions and providing a flatter and more accountable reporting structure. In addition, this realignment will support our focus on developing and implementing an interoperability roadmap, supporting care transformation and establishing a framework to support appropriate use of health data to further meaningful consumer engagement, system-level quality and safety of care, improvements in the public’s health and advancements in science,” wrote DeSalvo in a May 30 internal memo.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.